Annual EBITDA
$29.39 M
+$121.47 M+131.92%
December 31, 2024
Summary
- As of March 7, 2025, FOLD annual EBITDA is $29.39 million, with the most recent change of +$121.47 million (+131.92%) on December 31, 2024.
- During the last 3 years, FOLD annual EBITDA has risen by +$232.26 million (+114.49%).
- FOLD annual EBITDA is now at all-time high.
Performance
FOLD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$21.93 M
+$286.00 K+1.32%
December 31, 2024
Summary
- As of March 7, 2025, FOLD quarterly EBITDA is $21.93 million, with the most recent change of +$286.00 thousand (+1.32%) on December 31, 2024.
- Over the past year, FOLD quarterly EBITDA has stayed the same.
- FOLD quarterly EBITDA is now -34.77% below its all-time high of $33.63 million, reached on December 31, 2009.
Performance
FOLD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$29.39 M
+$38.58 M+419.62%
December 31, 2024
Summary
- As of March 7, 2025, FOLD TTM EBITDA is $29.39 million, with the most recent change of +$38.58 million (+419.62%) on December 31, 2024.
- Over the past year, FOLD TTM EBITDA has stayed the same.
- FOLD TTM EBITDA is now at all-time high.
Performance
FOLD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FOLD EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +131.9% | 0.0% | 0.0% |
| 3 y3 years | +114.5% | +331.1% | +122.1% |
| 5 y5 years | +108.8% | +331.1% | +122.1% |
FOLD EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +114.5% | at high | +130.5% | at high | +112.5% |
| 5 y | 5-year | at high | +108.8% | at high | +125.9% | at high | +108.8% |
| alltime | all time | at high | +106.9% | -34.8% | +108.1% | at high | +106.7% |
Amicus Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $29.39 M(-131.9%) | $21.93 M(+1.3%) | $29.39 M(-419.6%) |
| Sep 2024 | - | $21.65 M(+46.2%) | -$9.20 M(-77.2%) |
| Jun 2024 | - | $14.80 M(-151.1%) | -$40.33 M(-50.2%) |
| Mar 2024 | - | -$28.99 M(+74.1%) | -$80.95 M(-12.1%) |
| Dec 2023 | -$92.08 M(-53.9%) | -$16.65 M(+75.4%) | -$92.08 M(-30.8%) |
| Sep 2023 | - | -$9.49 M(-63.2%) | -$133.10 M(-6.2%) |
| Jun 2023 | - | -$25.82 M(-35.6%) | -$141.97 M(-15.4%) |
| Mar 2023 | - | -$40.12 M(-30.4%) | -$167.80 M(-15.9%) |
| Dec 2022 | -$199.58 M(-1.6%) | -$57.67 M(+214.2%) | -$199.58 M(-6.1%) |
| Sep 2022 | - | -$18.36 M(-64.5%) | -$212.52 M(-9.5%) |
| Jun 2022 | - | -$51.66 M(-28.2%) | -$234.95 M(+6.7%) |
| Mar 2022 | - | -$71.89 M(+1.8%) | -$220.28 M(+8.6%) |
| Dec 2021 | -$202.87 M(-16.5%) | -$70.61 M(+73.1%) | -$202.87 M(+4.0%) |
| Sep 2021 | - | -$40.79 M(+10.3%) | -$195.03 M(-6.3%) |
| Jun 2021 | - | -$36.98 M(-32.1%) | -$208.24 M(-2.9%) |
| Mar 2021 | - | -$54.49 M(-13.2%) | -$214.38 M(-11.8%) |
| Dec 2020 | -$242.98 M(-26.9%) | -$62.77 M(+16.2%) | -$242.98 M(-8.2%) |
| Sep 2020 | - | -$54.00 M(+25.3%) | -$264.82 M(-1.1%) |
| Jun 2020 | - | -$43.12 M(-48.1%) | -$267.73 M(-11.5%) |
| Mar 2020 | - | -$83.09 M(-1.8%) | -$302.67 M(-8.9%) |
| Dec 2019 | -$332.26 M(+3.0%) | -$84.60 M(+48.6%) | -$332.26 M(+5.5%) |
| Sep 2019 | - | -$56.92 M(-27.1%) | -$314.89 M(-23.5%) |
| Jun 2019 | - | -$78.06 M(-30.7%) | -$411.40 M(+5.7%) |
| Mar 2019 | - | -$112.69 M(+67.6%) | -$389.30 M(+20.7%) |
| Dec 2018 | -$322.47 M(-24.7%) | -$67.23 M(-56.2%) | -$322.47 M(+0.9%) |
| Sep 2018 | - | -$153.43 M(+174.2%) | -$319.46 M(-26.9%) |
| Jun 2018 | - | -$55.96 M(+22.0%) | -$437.18 M(+3.0%) |
| Mar 2018 | - | -$45.85 M(-28.6%) | -$424.31 M(-0.9%) |
| Dec 2017 | -$428.29 M(+119.5%) | -$64.22 M(-76.3%) | -$428.29 M(+1.3%) |
| Sep 2017 | - | -$271.15 M(+529.2%) | -$422.96 M(+115.5%) |
| Jun 2017 | - | -$43.09 M(-13.5%) | -$196.31 M(-3.2%) |
| Mar 2017 | - | -$49.82 M(-15.4%) | -$202.89 M(+4.0%) |
| Dec 2016 | -$195.14 M(+51.6%) | -$58.89 M(+32.4%) | -$195.14 M(+9.8%) |
| Sep 2016 | - | -$44.49 M(-10.4%) | -$177.72 M(+4.2%) |
| Jun 2016 | - | -$49.68 M(+18.1%) | -$170.61 M(+15.8%) |
| Mar 2016 | - | -$42.07 M(+1.5%) | -$147.37 M(+14.5%) |
| Dec 2015 | -$128.71 M | -$41.47 M(+10.9%) | -$128.71 M(+18.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2015 | - | -$37.39 M(+41.4%) | -$108.83 M(+23.9%) |
| Jun 2015 | - | -$26.44 M(+13.0%) | -$87.84 M(+16.7%) |
| Mar 2015 | - | -$23.41 M(+8.4%) | -$75.24 M(+12.3%) |
| Dec 2014 | -$67.01 M(+9.2%) | -$21.59 M(+31.7%) | -$67.01 M(+10.3%) |
| Sep 2014 | - | -$16.40 M(+18.4%) | -$60.74 M(+3.8%) |
| Jun 2014 | - | -$13.84 M(-8.8%) | -$58.50 M(-1.8%) |
| Mar 2014 | - | -$15.18 M(-1.0%) | -$59.55 M(-3.0%) |
| Dec 2013 | -$61.38 M(+22.2%) | -$15.33 M(+8.3%) | -$61.38 M(+4.2%) |
| Sep 2013 | - | -$14.15 M(-4.9%) | -$58.88 M(-2.8%) |
| Jun 2013 | - | -$14.89 M(-12.5%) | -$60.58 M(+11.0%) |
| Mar 2013 | - | -$17.01 M(+32.6%) | -$54.57 M(+8.6%) |
| Dec 2012 | -$50.24 M(+8.5%) | -$12.83 M(-19.1%) | -$50.24 M(+1.8%) |
| Sep 2012 | - | -$15.85 M(+78.4%) | -$49.33 M(+15.2%) |
| Jun 2012 | - | -$8.89 M(-29.9%) | -$42.83 M(-7.1%) |
| Mar 2012 | - | -$12.67 M(+6.3%) | -$46.12 M(-0.4%) |
| Dec 2011 | -$46.31 M(-13.9%) | -$11.92 M(+27.5%) | -$46.31 M(-7.5%) |
| Sep 2011 | - | -$9.35 M(-23.2%) | -$50.07 M(-9.8%) |
| Jun 2011 | - | -$12.17 M(-5.4%) | -$55.51 M(+2.7%) |
| Mar 2011 | - | -$12.86 M(-18.0%) | -$54.06 M(+0.6%) |
| Dec 2010 | -$53.76 M(+1193.2%) | -$15.69 M(+6.2%) | -$53.76 M(+1110.4%) |
| Sep 2010 | - | -$14.78 M(+37.7%) | -$4.44 M(+81.6%) |
| Jun 2010 | - | -$10.73 M(-14.5%) | -$2.44 M(-48.8%) |
| Mar 2010 | - | -$12.56 M(-137.3%) | -$4.78 M(+14.9%) |
| Dec 2009 | -$4.16 M(-89.0%) | $33.63 M(-363.0%) | -$4.16 M(-91.2%) |
| Sep 2009 | - | -$12.78 M(-2.1%) | -$47.39 M(+8.9%) |
| Jun 2009 | - | -$13.06 M(+9.4%) | -$43.52 M(+7.2%) |
| Mar 2009 | - | -$11.94 M(+24.3%) | -$40.62 M(+7.9%) |
| Dec 2008 | -$37.64 M(-15.5%) | -$9.60 M(+7.7%) | -$37.64 M(-8.7%) |
| Sep 2008 | - | -$8.92 M(-12.2%) | -$41.21 M(-5.9%) |
| Jun 2008 | - | -$10.16 M(+13.3%) | -$43.79 M(+0.4%) |
| Mar 2008 | - | -$8.97 M(-31.9%) | -$43.60 M(-2.2%) |
| Dec 2007 | -$44.57 M(-2.9%) | -$13.17 M(+14.6%) | -$44.57 M(+41.9%) |
| Sep 2007 | - | -$11.49 M(+15.2%) | -$31.40 M(+57.7%) |
| Jun 2007 | - | -$9.97 M(+0.4%) | -$19.91 M(+100.4%) |
| Mar 2007 | - | -$9.94 M | -$9.94 M |
| Dec 2006 | -$45.91 M(+127.7%) | - | - |
| Dec 2005 | -$20.16 M(+211.8%) | - | - |
| Dec 2003 | -$6.47 M | - | - |
FAQ
- What is Amicus Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Amicus Therapeutics?
- What is Amicus Therapeutics annual EBITDA year-on-year change?
- What is Amicus Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly EBITDA year-on-year change?
- What is Amicus Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Amicus Therapeutics?
- What is Amicus Therapeutics TTM EBITDA year-on-year change?
What is Amicus Therapeutics annual EBITDA?
The current annual EBITDA of FOLD is $29.39 M
What is the all time high annual EBITDA for Amicus Therapeutics?
Amicus Therapeutics all-time high annual EBITDA is $29.39 M
What is Amicus Therapeutics annual EBITDA year-on-year change?
Over the past year, FOLD annual EBITDA has changed by +$121.47 M (+131.92%)
What is Amicus Therapeutics quarterly EBITDA?
The current quarterly EBITDA of FOLD is $21.93 M
What is the all time high quarterly EBITDA for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly EBITDA is $33.63 M
What is Amicus Therapeutics quarterly EBITDA year-on-year change?
Over the past year, FOLD quarterly EBITDA has changed by $0.00 (0.00%)
What is Amicus Therapeutics TTM EBITDA?
The current TTM EBITDA of FOLD is $29.39 M
What is the all time high TTM EBITDA for Amicus Therapeutics?
Amicus Therapeutics all-time high TTM EBITDA is $29.39 M
What is Amicus Therapeutics TTM EBITDA year-on-year change?
Over the past year, FOLD TTM EBITDA has changed by $0.00 (0.00%)